Multidisciplinary Team Essentials on CMV Prevention, Surveillance, and Treatment Optimization in the Transplant Setting

Provided by the Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant from Merck & Co., Inc.


July 8, 2024

Expiration Date

July 8, 2025


The role of the multidisciplinary transplant team, including transplant pharmacists, has expanded considerably over the past decade to keep pace with advances in the field and to address long-term care of transplant recipients. Despite these advances, breakthrough cytomegalovirus (CMV) infections and development of refractory and resistant CMV infections cause significant complications post-transplant. Transplant pharmacists can play a significant part in improving patient outcomes in multiple ways before, during, and after transplant including medication assessment and reconciliation, mitigating drug-drug interactions, dose optimization, antimicrobial stewardship, and ongoing patient education. To meet the needs of transplant pharmacists, this education offers personalized education with nuanced pathways applicable to solid organ and hematopoietic stem cell transplant (HSCT) settings. Learners will complete a brief assessment to inform targeted areas of educational need and then be able to build their own customized slide deck, allowing them to bypass areas of established knowledge and focus on areas of greatest interest or relevance to their clinical practice. 


This activity is intended for healthcare providers who care for patients with cytomegalovirus (CMV) infection, solid organ and hematopoietic stem cell transplant specialists/surgeons, hematologists/oncologists, nephrologists, infectious disease specialists, transplant pharmacists, internal medicine and primary care physicians, nurses, and advanced practice providers (NPs/PAs).


Cytomegalovirus (CMV) infection is a serious complication with implications for morbidity and mortality in patients who have recently undergone solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Post-transplant CMV can cause tissue-invasive disease, including pneumonia, hepatitis, gastroenteritis, retinitis, and encephalitis, which can develop at various times (early and late) after the procedure. In addition, patients who develop a CMV infection ≥100 days after transplantation have been shown to have a 4.8-fold increased risk of death compared with those who do not develop late CMV. Advancements in prophylaxis and treatment have the potential to greatly improve outcomes but require patient monitoring and optimal treatment selection. This customized education program, developed for multidisciplinary teams, will provide clinicians involved in the management of transplant patients to with targeted interventions to address knowledge and competency gaps in CMV infection risks, prophylaxis, and treatment strategies.


Upon completion of this activity, pharmacists will be able to:

  • Identify patients at risk for CMV infection following a solid organ or hematopoietic stem cell transplant
  • Describe potential consequences and risk posed by CMV infection in post-transplant patients
  • Review and discuss the latest evidence for the prophylaxis of patients at risk for CMV infection post-transplant
  • Create effective prophylaxis regimens for patients at risk for CMV infection post-transplant
  • Formulate individualized treatment plans for post-transplant patients with CMV infection who are refractory to treatment


  • CMV infection in post-transplant patients
  • Prophylaxis vs preemptive therapy (PET)
  • Approved treatments for CMV infection
  • Treatment strategies
  • Roles of the MDT
  • Future directions


Fernanda P. Silveira, MD, MS, FIDSA, FAST (Chair)
Professor of Medicine
Transplant Infectious Diseases Physician
Clinical Operations Director, Transplant Infectious Diseases
Division of Infectious Diseases
University of Pittsburgh and UPMC
Pittsburgh, PA
Roy F Chemaly, MD, MPH, FIDSA, FACP
Professor and Chair
G. P. Bodey, Sr. Distinguished Professorship in Infectious Diseases
Director, Clinical Virology Research
Department of Infectious Diseases, Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
Raymund R. Razonable, MD
Professor of Medicine
Mayo Clinic College of Medicine and Science
Program Director, Mayo Clinic Infectious Diseases Fellowship Program
Mayo Clinic
Rochester, MN


The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

The following financial relationships have been provided:
Fernanda P. Silveira, MD, MS (Chair) 
Sources of Funding for Research/Grants: Ansun Biopharma, Inc., Glaxo Smith Kline, Merck & Co. Inc.
Consulting Agreements: Takeda
Advisory Board Member: Eurofins Viracor

Roy F Chemaly, MD, MPH, FIDSA, FACP
Advisor: ADMA Biologics, Inc., AiCuris, Ansun Biopharma, Moderna Therapeutics, Merck, Shionogi, Inc., Tether Therapeutics
Sources of Funding for Research/Grants: ADMA Biologics, Inc., AiCuris, Ansun Biopharma, Eurofins Viracor, LLC, Genetech, Karius, Moderna Therapeutics, Merck, Oxford Immunotec, Shionogi, Inc., Takeda, Tether Therapeutics   
Consulting Agreements: ADMA Biologics, Inc., AiCuris, Ansun Biopharma, Eurofins Viracor, LLC,  Karius, Moderna Therapeutics, Oxford Immunotec, Shionogi, Inc., Takeda, Tether Therapeutics  
Speakers' Bureau: Eurofins Viracor, LLC, Merck, Takeda

Raymund R. Razonable, MD
Sources of Funding for Research/Grant: Gilead, Regeneron, Roche
Advisory Board: AlloVir, Novartis


ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.


acpeThe Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 2.0 contact hours.

ACPE Universal Activity Number: 0396-0000-24-009-H01-P
Activity Type: Application

Method of Participation

To receive credit, learners are required to complete the assessment, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. Your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records.  There is no fee to participate in the activity or for the generation of the certificate. Partial credit may not be awarded for CPE credit; participation in the complete activity is required to receive credit.

For questions, contact Karen Catino at


The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: Valganciclovir, foscarnet, and cidofovir are not approved for the treatment of CMV infection/disease in HSCT; letermovir is not approved for the treatment of CMV disease and is not approved for CMV prophylaxis in solid organ transplant except kidney transplant; maribavir is not approved for prophylaxis or initial treatment of CMV infection/disease


© 2024 Academy for Continued Healthcare Learning

Academy for Continued Healthcare Learning
308 S Jefferson St, Suite 312
Chicago, IL 60661-5605
Ph (877) 444-8435